Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
FCC Exempts Select Foreign-Made Drones From U.S. Import Ban Until 2026 
SAN DIEGO, March 17, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) will provide a live webcast of its fourth quarter financial results and business update on Thursday, March 23, 2017 at 5:30 PM Eastern Time.
The dial-in information is as follows:
Dial-In Number: +1.877.402.3914
Conference ID: 90778155
Prior to the webcast at approximately 4:30 PM Eastern Time on March 23rd, Cytori will issue its fourth quarter earnings release which will review Cytori’s fourth quarter performance. The webcast will be available both live and by replay two hours after the call in the “Webcasts” section of the company’s investor relations website.
About Cytori Therapeutics, Inc.
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications using technology that allows Cytori to use the benefits of its encapsulation platform to develop novel therapeutic strategies and reformulate other drugs to optimize their clinical properties. For more information, visit www.cytori.com.
Cytori Therapeutics, Inc. Tiago Girao, 1.858.458.0900 [email protected]
